{"doi":"10.1002/mds.28196","title":"Glycopyrrolate Improves Disability From Sialorrhea in Parkinson's Disease: A <scp>12‐Week</scp> Controlled Trial","abstract":"<jats:title>Abstract</jats:title><jats:sec><jats:title>Objective</jats:title><jats:p>The objective of this study was to assess the 12‐week efficacy and safety of oral glycopyrrolate for moderate‐to‐severe sialorrhea in Parkinson's disease (PD).</jats:p></jats:sec><jats:sec><jats:title>Background</jats:title><jats:p>Chronic moderate‐to‐severe sialorrhea has a negative impact on quality of life in PD. There is no robust evidence for oral treatments for sialorrhea longer than 1 week.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>This was a 12‐week, double‐blinded, placebo‐controlled, parallel phase II study in patients with PD and Movement Disorder Society–Unified Parkinson's Disease Rating Scale item 2.2 &gt; 2. The intervention was glycopyrrolate up to 4.5 mg/d; the primary outcome was sialorrhea related–disability (Radboud Oral Motor Inventory for Parkinson's Disease–Saliva). We used an intention‐to‐treat analysis. A <jats:italic>P</jats:italic> &lt; 0.05 was deemed significant.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>We recruited 28 patients (age, 71.1 ± 6.9 years; PD duration, 11.4 ± 7.2 years; Radboud Oral Motor Inventory for Parkinson's Disease–Saliva, 22.4 ± 5.7). Glycopyrrolate was superior to placebo at 12 weeks in the Radboud Oral Motor Inventory for Parkinson's Disease–Saliva (between‐group difference, 5.3; 95% confidence interval, 1.0–9.6). Dry mouth was the most common adverse event (glycopyrrolate, n = 6; placebo, n = 2).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>The results support the efficacy of glycopyrrolate to treat sialorrhea‐related disability up to 12 weeks and contribute to addressing unmet nonmotor care needs in PD. © 2020 International Parkinson and Movement Disorder Society</jats:p></jats:sec>","journal":"Movement Disorders","year":2020,"id":641208,"datarank":0.47670807455219194,"base_score":3.1780538303479458,"endowment":3.1780538303479458,"self_citation_contribution":0.47670807455219194,"citation_network_contribution":0.0,"self_endowment_contribution":0.47670807455219194,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":23,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1095781,"name":"Maria Eliza Freitas","orcid":"0000-0003-3315-0892","position":1,"is_corresponding":false},{"id":1666955,"name":"Ahmed Basndwah","orcid":null,"position":2,"is_corresponding":false},{"id":1666956,"name":"Marta Ruiz Lopez","orcid":null,"position":3,"is_corresponding":false},{"id":1666957,"name":"Lais Machado de Oliveira","orcid":"0000-0002-1980-6755","position":4,"is_corresponding":false},{"id":1666958,"name":"Duha Mohammed Al‐Shorafat","orcid":null,"position":5,"is_corresponding":false},{"id":1666959,"name":"Tinghua Zhang","orcid":null,"position":6,"is_corresponding":false},{"id":1666960,"name":"Jane P. Lui","orcid":null,"position":7,"is_corresponding":false},{"id":1666961,"name":"David Grimes","orcid":null,"position":8,"is_corresponding":false},{"id":1377367,"name":"Susan H. Fox","orcid":"0000-0003-4779-4269","position":9,"is_corresponding":false},{"id":523733,"name":"Tiago Mestre","orcid":"0000-0002-6973-7479","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Glycopyrrolate Improves Disability From Sialorrhea in Parkinson's Disease: A <scp>12‐Week</scp> Controlled Trial","abstract":"<jats:title>Abstract</jats:title><jats:sec><jats:title>Objective</jats:title><jats:p>The objective of this study was to assess the 12‐week efficacy and safety of oral glycopyrrolate for moderate‐to‐severe sialorrhea in Parkinson's disease (PD).</jats:p></jats:sec><jats:sec><jats:title>Background</jats:title><jats:p>Chronic moderate‐to‐severe sialorrhea has a negative impact on quality of life in PD. There is no robust evidence for oral treatments for sialorrhea longer than 1 week.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>This was a 12‐week, double‐blinded, placebo‐controlled, parallel phase II study in patients with PD and Movement Disorder Society–Unified Parkinson's Disease Rating Scale item 2.2 &gt; 2. The intervention was glycopyrrolate up to 4.5 mg/d; the primary outcome was sialorrhea related–disability (Radboud Oral Motor Inventory for Parkinson's Disease–Saliva). We used an intention‐to‐treat analysis. A <jats:italic>P</jats:italic> &lt; 0.05 was deemed significant.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>We recruited 28 patients (age, 71.1 ± 6.9 years; PD duration, 11.4 ± 7.2 years; Radboud Oral Motor Inventory for Parkinson's Disease–Saliva, 22.4 ± 5.7). Glycopyrrolate was superior to placebo at 12 weeks in the Radboud Oral Motor Inventory for Parkinson's Disease–Saliva (between‐group difference, 5.3; 95% confidence interval, 1.0–9.6). Dry mouth was the most common adverse event (glycopyrrolate, n = 6; placebo, n = 2).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>The results support the efficacy of glycopyrrolate to treat sialorrhea‐related disability up to 12 weeks and contribute to addressing unmet nonmotor care needs in PD. © 2020 International Parkinson and Movement Disorder Society</jats:p></jats:sec>","is_dataset_classified":null,"base_score":3.1780538303479458,"endowment":3.1780538303479458,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"32657457","pmcid":null,"openalex_id":"https://openalex.org/W3042481868","authors":[],"funders":[{"funder_name":"Movement Disorders Research Fund, Toronto General and Western Hospital Foundation","grant_id":"","title":null},{"funder_name":"Parkinson Research Consortium","grant_id":"","title":null}],"total_grants":2,"fwci":0.9207,"citation_percentile":0.78917977,"influential_citations":0,"citation_trend":[{"year":2020,"count":1},{"year":2021,"count":2},{"year":2022,"count":4},{"year":2023,"count":4},{"year":2024,"count":2},{"year":2025,"count":7},{"year":2026,"count":3}],"oa_status":"closed","license":"http://onlinelibrary.wiley.com/termsAndConditions#vor","oa_locations":[{"url":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fmds.28196","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/mds.28196","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/full-xml/10.1002/mds.28196","host_type":"publisher"},{"url":"https://movementdisorders.onlinelibrary.wiley.com/doi/pdf/10.1002/mds.28196","host_type":"publisher"},{"url":"https://doi.org/10.1002/mds.28196","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/32657457","host_type":"repository"}],"fields_of_study":["Botulinum Toxin and Related Neurological Disorders","Salivary Gland Disorders and Functions","Parkinson's Disease Mechanisms and Treatments","Aged","Double-Blind Method","Glycopyrrolate","Humans","Middle Aged","Parkinson Disease","Quality of Life","Saliva","Sialorrhea","Treatment Outcome"],"mesh_terms":["Aged","Double-Blind Method","Glycopyrrolate","Humans","Middle Aged","Parkinson Disease","Quality of Life","Saliva","Sialorrhea","Treatment Outcome"],"keywords":["Glycopyrrolate","Sialorrhea","Parkinson's disease","Medicine","Physical therapy","Physical medicine and rehabilitation","Psychology","Anesthesia","Disease","Internal medicine","Atropine","Parkinson disease","Randomized controlled trial","Nonmotor"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-07T16:36:53.974704Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}